Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Completes Equity Purchase Of Ranbaxy, Closing Deal

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo now owns 63.92 percent of Ranbaxy Laboratories equity after buying the last piece of stock in the $4 billion takeover of India's largest generics maker. Daiichi president Takashi Shoda said all of the planned transactions of the deal have now been completed. For its part, Ranbaxy is expected to use the Daiichi funds to retire some of its debt as it works to create what Malvinder Mohan Singh, Ranbaxy managing director, said would be a hybrid business model. The hybrid company is intended to take advantage of opportunities in all parts of the pharmaceutical chain, the firm said. (Click here for more - a subscription may be required

You may also be interested in...



Sun Adds To Criticism Over Medicare 505(b)(2) Policy

Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.

Bluebird’s Eli-Cel Gene Therapy Among Myriad New Drugs Seeking EU Approval

An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.

Peptomyc Battles Cancer R&D Conventions

Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel